Benzinga | May 6, 2021 08:39AM EDT

Roth Capital Maintains Buy on Global Blood Therapeutics, Lowers Price Target to $124

Roth Capital analyst Elemer Piros maintains Global Blood Therapeutics (NASDAQ:GBT) with a Buy and lowers the price target from $128 to $124.